XENETIC BIOSCIENCE, INCORPORATED LEDGEMONT RESEARCH CENTER LEXINGTON, MACommencement Date Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
* Notwithstanding the Base Rent for the first Lease Year set forth above, so long as Tenant is not in default of this Lease beyond any applicable notice and cure period(s), Tenant shall be entitled to an abatement of the monthly installment of Base Rent (but not Operating Expenses, Taxes or other amounts due hereunder, to the extent same are payable pursuant hereto), or so-called “free rent” period, for the first full month of the Lease Term (“Free Rent Period”).
1) LIPOXEN PLC (2) LIPOXEN TECHNOLOGIES LTD - and - (2) SERUM INSTITUTE OF INDIA LIMITED Exclusive Patent And Know How Licence and Manufacturing AgreementAgreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled • New York
and - SERVICE AGREEMENTService Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
AGREEMENT ON CO-DEVELOPMENT AND THE TERMS OF EXCLUSIVE LICENCE between - and-Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
Counterpart Lease relating to 3rd Floor Rear, Greener House, 68 Haymarket, London SW1 Dated 20 March 2012 Her Majesty the Queen (1) The Crown Estate Commissioners (2) Xenetic Biosciences plc (3)Xenetic Biosciences, Inc. • April 15th, 2014 • Air transportation, nonscheduled
DATED: 3 November 2009 - and - SERVICE AGREEMENTService Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
1) LIPOXEN TECHNOLOGIES LTD - and - (2) PHARMASYNTHEZ ZAO COLLABORATION, LICENCE AND DEVELOPMENT AGREEMENTDevelopment Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled • England and Wales
DATED 4 August 2011 SUBSCRIPTION AGREEMENT in respect of ordinary shares in the capital of Lipoxen plcAgreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
ContractXenetic Biosciences, Inc. • April 15th, 2014 • Air transportation, nonscheduled
This [***] (this “Agreement”), dated as of January 29, 2014, is by and among Xenetic Biosciences, Inc., a Nevada corporation (the “Company”), and Baxter Healthcare SA (the “Investor”).
LETTER AGREEMENTLetter Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
SIXTH AMENDMENT TO THE EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
This Sixth Amendment to Exclusive Research, Development and License Agreement (this “Sixth Amendment”) is made and entered into as of this 29th day of January, 2014 by and among Baxter Healthcare SA, a Swiss corporation having a principal place of business at Postfach, 8010, Zurich, Switzerland (hereinafter “BHSA”) Baxter Healthcare Corporation, a Delaware corporation having a principal place of business at 1 Baxter Parkway, Deerfield, Illinois (“BHC” and together with BHSA, “Baxter”) and Lipoxen Technologies Limited, having a place of business at London Bioscience Innovation Centre, 2 Royal College Street, London NW1 ONH, England (hereinafter “Lipoxen”) to amend the terms of that certain Exclusive Research, Development and License Agreement, dated August 15, 2005 among, Lipoxen and Baxter (the “Agreement”) (as amended). Baxter and Lipoxen are each referred to herein as a “Party” and collectively as the “Parties”.
EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled • Illinois
This Agreement (“AGREEMENT”) is made and entered into August 15, 2005 (the “EFFECTIVE DATE”) by and between Lipoxen Technologies Limited, a company registered in England and Wales with company number 03401495 and having its registered office at Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB (“LIPOXEN”); Baxter Healthcare SA (“BHSA”), a corporation organized and existing under the laws of Switzerland, and Baxter Healthcare Corporation (“BHC”) having its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015 (BHSA and BHC collectively referred to as “BAXTER”). LIPOXEN and BAXTER may be referred to herein individually as a “PARTY” and collectively as the “PARTIES.”
FROM: [ILLEGIBLE] PHONE NO. : 00442076811314 13 DEC. 2006 01: 58 PM P1Xenetic Biosciences, Inc. • April 15th, 2014 • Air transportation, nonscheduled
This is an amendment to the Research, Development and License Agreement (“R&L AGREEMENT”) entered into on August 15, 2005, by and between Lipoxen Technologies Limited, a company registered in England and [ILLEGIBLE] with company number 03401495 and having its registered office at suit [ILLEGIBLE] WC1H [ILLEGIBLE] (“LIPOXEN”); [ILLEGIBLE] Healthcare SA (“BHSA”), a corporation organized and existing under the laws of Switzerland, and Baxter Healthcare Corporation (“BHC”) having its principal place of business at One [ILLEGIBLE] Parkway, [ILLEGIBLE], [ILLEGIBLE]
DATED 23 JANUARY 2014 and DIRECTOR APPOINTMENT AGREEMENTDirector Appointment Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled • Nevada
DATED SEPTEMBER, 15 2010 LIPOXEN TECHNOLOGIES, LTD. - and - BAXTER HEALTHCARE CORPORATION AND BAXTER HEALTHCARE SA AMENDMENT NUMBER FIVE TO THE EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENTStock Purchase Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled • Nevada
This AMENDMENT NO. 1 (this “Amendment”), dated as of February 14, 2014, [***], dated as of January 29, 2014 (the “Agreement”), by and between Xenetic Biosciences, Inc., a Nevada corporation (the “Company”), and Baxter Healthcare SA (the “Investor”).
DATED AUGUST, 10 2010 LIPOXEN TECHNOLOGIES, LTD. - and - BAXTER HEALTHCARE CORPORATION AND BAXTER HEALTHCARE SA AMENDMENT NUMBER FOUR TO THE EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
MASTER CLINICAL RESEARCH SERVICES AGREEMENTMaster Clinical Research Services Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
This Master Clinical Research Services Agreement (“Agreement”) made this 6th day of February 2013 (“Effective Date”) by and between Novotech (Australia) Pty Limited with principal offices located at Level 3, 235 Pyrmont Street, Pyrmont, NSW 2009 Australia (“Novotech”), and Xenetic Biosciences Plc, with principal offices located at Greener House, 66-68 Haymarket, London, W 1Y 4RF, (“Company”).
SECOND AMENDMENT TO EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
This SECOND AMENDMENT TO EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment”) is made and entered into as of this 28TH day of May, 2009 by and among Lipoxen Technologies Limited, a company registered in England and Wales with company number 03401495 and having its registered office at London Bioscience Innovation Centre, 2 Royal College St., London NWI ONH, England (“Lipoxen”); Baxter Healthcare SA (“BHSA”), a corporation organized and existing under the laws of Switzerland, and Baxter Healthcare Corporation (“BHC”) having its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015 (BHSA and BHC collectively referred to as “Baxter”) to amend the terms of that certain Exclusive Research, Development and License Agreement between the Parties dated August 15, 2005, which was amended pursuant to that certain amendment between the parties dated on or about December 15, 2006 (together the “Agreement”). Lipoxen and Baxter may be referred to herein indi
